Phreesia (Phreesia) EPS (Diluted) : $-2.51 (TTM As of Jan. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Phreesia EPS (Diluted)?

Phreesia's Earnings per Share (Diluted) for the three months ended in Jan. 2024 was $-0.55. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 was $-2.51.

Phreesia's EPS (Basic) for the three months ended in Jan. 2024 was $-0.55. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jan. 2024 was $-2.51.

Phreesia's EPS without NRI for the three months ended in Jan. 2024 was $-0.55. Its EPS without NRI for the trailing twelve months (TTM) ended in Jan. 2024 was $-2.51.

During the past 3 years, the average EPS without NRIGrowth Rate was -53.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was 26.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 7 years, Phreesia's highest 3-Year average EPS without NRI Growth Rate was 69.50% per year. The lowest was -53.50% per year. And the median was 30.80% per year.

Phreesia EPS (Diluted) Historical Data

The historical data trend for Phreesia's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phreesia EPS (Diluted) Chart

Phreesia Annual Data

Trend

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

Jan24

EPS (Diluted)

Get a 7-Day Free Trial

-4.50

-0.69

-2.37

-3.36

-2.51

Phreesia Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
EPS (Diluted)	Get a 7-Day Free Trial															-0.72	-0.70	-0.68	-0.58	-0.55

Competitive Comparison of Phreesia's EPS (Diluted)

For the Health Information Services subindustry, Phreesia's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Phreesia's PE Ratio Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Phreesia's PE Ratio distribution charts can be found below:

* The bar in red indicates where Phreesia's PE Ratio falls into.

Phreesia EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Phreesia's Diluted EPS for the fiscal year that ended in Jan. 2024 is calculated as

Diluted EPS (A: Jan. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-136.885	-	0)	/	54.561
	=	-2.51

Phreesia's Diluted EPS for the quarter that ended in Jan. 2024 is calculated as

Diluted EPS (Q: Jan. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-30.646	-	0)	/	55.827
	=	-0.55

EPS (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.51

Phreesia (NYSE:PHR) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Phreesia EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Phreesia's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Phreesia (Phreesia) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Phreesia Inc (NYSE:PHR) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

19P:Germany 19P:Germany

Address

1521 Concord Pike, Suite 301 PMB 221, Wilmington, DE, USA, 19803

Website

https://www.phreesia.com

Phreesia Inc is a provider of comprehensive software solutions that improves the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, but not limited to, initial patient contact, registration, appointment scheduling, payments, and post-appointment patient surveys.

Executives

Balaji Gandhi	officer: Chief Financial Officer	PHREESIA, INC., 1521 CONCORD PIKE, SUITE 301, PMB 221, WILMINGTON DE 19803
Allison C Hoffman	officer: General Counsel & Secretary	315 EAST 68TH STREET, NEW YORK NY 10065
Amy Beth Vanduyn	officer: SVP, Human Resources	C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Chaim Indig	director, officer: Chief Executive Officer	C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Michael J. Davidoff	officer: See Remarks	C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
David Linetsky	officer: SVP, Life Sciences	C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Evan Roberts	officer: Chief Operating Officer	C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Janet Gunzburg	officer: Principal Accounting Officer	BANKRATE, INC., 477 MADISON AVENUE, SUITE 430, NEW YORK NY 10022
Lisa Egbuonu-davis	director	C/O OMEGA HEALTHCARE INVESTORS, INC., 303 INTERNATIONAL CIRCLE, SUITE 200, HUNT VALLEY MD 21030
Gillian Munson	director	C/O XO GROUP INC., 195 BROADWAY, 25TH FLOOR, NEW YORK NY 10007
Mark Douglas Smith	director	C/O TELADOC HEALTH, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Randy Rasmussen	officer: Chief Financial Officer	PHREESIA, INC., 434 FAYETTEVILLE ST., SUITE 1400, RALEIGH NC 27601
Ramin Sayar	director	305 MAIN STREET, REDWOOD CITY CA 94063
Michael Weintraub	director	C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Edward L Cahill	10 percent owner	C/O HLM VENTURE PARTNERS, 800 SOUTH STREET, SUITE 200, WALTHAM MA 02453